NCT05675410 2026-04-13
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
Immatics US, Inc.
University College, London
Suzhou BlueHorse Therapeutics Co., Ltd.
Advenchen Laboratories, LLC
Takeda